Psyched Wellness LTD. Adds Kevin Feeney to the Advisory Board

Toronto, Ontario, November 25, 2020Psyched Wellness Ltd. (formerly Duncan Park Holdings Corporation) (CSE:PSYC, OTC Pink: DCNPF) (the “Company” or “Psyched”) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that Kevin Feeney has joined the advisory board of the Company to work with the team on identifying novel uses for Muscimol, the psychoactive constituent of Amanita Muscaria.

“When Jeff and David contacted me about Psyched Wellness and their interest in the therapeutic potential of the famed Amanita muscaria mushroom, I was enthused,” says Kevin Feeney. “Amanita Muscaria has a long history of use for treating a number of ailments including anxiety, insomnia, pain, and inflammation. While this mushroom has been largely overlooked in both standard and alternative medicines, its potential applications are rich and largely unexplored, and shows promise in such disparate areas as treating alcohol and benzodiazepine withdrawal as well as alleviating cognitive impairments related to Lyme disease and Alzheimer’s. I look forward to working with Jeff, David, and the rest of the Psyched Wellness team to explore this underappreciated medicine and help bring a quality product to market.”

Kevin Feeney, PhD, JD, is a cultural anthropologist and lawyer currently working as a Program Director and Instructor in Interdisciplinary Studies – Social Sciences at Central Washington University. His primary research interests include examining legal and regulatory issues surrounding the religious and cultural use of psychoactive substances, with an emphasis on peyote and ayahuasca, and exploring modern and traditional uses of Amanita muscaria, with a specific focus on medicinal use and preparation practices. He has recently published an edited volume on Amanita muscaria (Fly Agaric: A Compendium of History, Pharmacology, Mythology, and Exploration) and has also been published in the International Journal of Drug Policy, Journal of Psychoactive Drugs, Human Organization, and Curare, among other books and journals (Research articles and other writings can be found at: He is a current board member of Cactus Conservation Institute, which is dedicated to the study and preservation of vulnerable cacti and is also a member of Chacruna’s Council for the Protection of Sacred Plants.

“Adding Kevin to our team is a key development in the growth of the company as we look to expand our understanding of the medicinal potential of Amanita Muscaria,” says Jeff Stevens, CEO of the Company. “His experience studying psychoactive substances and specifically Amanita Muscaria is key to identifying new novel uses of the compound for various health and wellness applications.”

The Company has also issued 750,000 options at a strike price of $0.185 to certain advisors and consultants.